Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study

Kristen J Wells^{1

2

3}, Tonya M Pan^{4

5}, Coralia Vázquez-Otero⁶, Danielle Ung⁶, Amy E Ustjanauskas^{4

5}, Dariana Muñoz⁷, Christine Laronga^{6

8}, Richard G Roetzheim^{6

8}, Marissa Goldenstein⁹, Claudia Carrizosa⁷, Sumayah Nuhaily¹⁰, Kenneth Johnson¹¹, Marilyn Norton¹¹, Elizabeth Sims¹², Gwendolyn P Quinn^{6

8}

Affiliations

¹ Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA. kwells@mail.sdsu.edu.
² University of California, San Diego Moores Cancer Center, La Jolla, CA, USA. kwells@mail.sdsu.edu.
³ SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA. kwells@mail.sdsu.edu.
⁴ University of California, San Diego Moores Cancer Center, La Jolla, CA, USA.
⁵ SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.
⁶ University of South Florida, Tampa, FL, USA.
⁷ , San Diego State University Research Foundation, San Diego, CA, USA.
⁸ Moffitt Cancer Center, Tampa, FL, USA.
⁹ Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA.
¹⁰ Emory University, Atlanta, GA, USA.
¹¹ , South County Oncology and Hematology, Chula Vista, CA, USA.
¹² Sharp HealthCare, San Diego, CA, USA.

PMID: 27146492
PMCID: PMC4995114
DOI: 10.1007/s00520-016-3229-8

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study

Kristen J Wells et al. Support Care Cancer. 2016 Oct.

. 2016 Oct;24(10):4123-30.

doi: 10.1007/s00520-016-3229-8. Epub 2016 May 5.

Authors

Affiliations

¹ Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA. kwells@mail.sdsu.edu.
² University of California, San Diego Moores Cancer Center, La Jolla, CA, USA. kwells@mail.sdsu.edu.
³ SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA. kwells@mail.sdsu.edu.
⁴ University of California, San Diego Moores Cancer Center, La Jolla, CA, USA.
⁵ SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.
⁶ University of South Florida, Tampa, FL, USA.
⁷ , San Diego State University Research Foundation, San Diego, CA, USA.
⁸ Moffitt Cancer Center, Tampa, FL, USA.
⁹ Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA.
¹⁰ Emory University, Atlanta, GA, USA.
¹¹ , South County Oncology and Hematology, Chula Vista, CA, USA.
¹² Sharp HealthCare, San Diego, CA, USA.

PMID: 27146492
PMCID: PMC4995114
DOI: 10.1007/s00520-016-3229-8

Abstract

Purpose: To evaluate the barriers and facilitators to taking anti-hormonal medications among medically and historically underserved breast cancer survivors within the first 5 years post chemotherapy, radiation, and/or surgery.

Methods: The current study was framed within the National Institutes of Health Centers for Population Health and Health Disparities Model (NIHCPHHD Model). Twenty-five historically or medically underserved breast cancer survivors participated in an in-depth interview, in either English or Spanish. Interviews were audio recorded and transcribed verbatim. Interview data were analyzed using content analysis.

Results: Anti-hormonal medication adherence was facilitated in several ways, including establishing a routine of medication taking, leaving the medicine in a visible or easily accessible place, taking the medication with other medications, reducing the cost of medicine, using a pillbox, understanding the negative consequences of lack of adherence, and having positive interactions with physicians. Side effects were the most commonly mentioned barrier to medication adherence.

Conclusions: Similar to other research, this qualitative study of medically and historically underserved breast cancer survivors in the USA found that side effects are the most frequently endorsed barrier to anti-hormonal medication adherence. Conversely, there were a number of facilitators of correct and consistent anti-hormonal medication use. The management of side effects is critically important to increase adherence to anti-hormonal medications. Health care providers, support providers, and caregivers can encourage breast cancer survivors to better adhere to anti-hormonal medications using a number of approaches that have been successful for other women.

Keywords: Breast cancer; Breast neoplasms; Cancer; Medication adherence; Oncology.

PubMed Disclaimer

Conflict of interest statement

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R21CA161077, U54 CA132384, and U54 CA132379 and the Bankhead-Coley Cancer Research Program, Florida Department of Health under award number 2BN05. Ms. Coralia Vázquez-Otero’s effort was supported by a National Cancer Institute diversity supplement 3R21CA16077-01A1S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Florida Department of Health. The University of California, San Diego San Diego Fellowship funded the effort of Ms. Tonya Pan. Kristen J. Wells, Tonya M. Pan, Coralia Vázquez-Otero, Danielle Ung, Amy Ustjanauskas, Dariana Muñoz, Christine Laronga, Richard G. Roetzheim, Marissa Bredice, Claudia Carrizosa, Sumayah Nuhaily, Kenneth Johnson, Marilyn Norton, Elizabeth Sims, and Gwendolyn P. Quinn declare they have no conflict of interest.

References

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2011. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. - PubMed
1. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol. 2010;28:2784–95. - PMC - PubMed
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. 2010 V.2.2010. [cited 2010 Mar 16]; Available from: http://www.nccn.org.
1. Winer EP. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004. J Clin Oncol. 2004;23:619–29. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study

Affiliations

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical